Normal view MARC view ISBD view

The potential contribution of ranolazine to Torsade de Pointe.

MedStar author(s):

Citation: Journal of Cardiovascular Disease Research. 4(3):187-90, 2013 Sep.PMID: 24396259Institution: MedStar Harbor HospitalDepartment: MedicineForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2013 ISSN:

0975-3583

Name of journal: Journal of cardiovascular disease researchAbstract: Ranolazine is a novel anti-anginal agent acting through pharmacologic mechanism of inhibition of the late phase of the inward sodium current. In addition, it is a potent inhibitor of rapid delayed rectifier potassium currents, leading to prolongation of the QT interval. However, ranolazine has not yet described to be associated with Torsade de Pointes despite its QT-prolonging effect. In this case report, we describe a patient on ranolazine who developed Torsade de Pointes and discuss about the potential contribution of ranolazine to the development of Torsade de Pointes.All authors: Liu Z, Rosen BD, Williams RBFiscal year: FY2014Digital Object Identifier:

https://dx.doi.org/10.1016/j.jcdr.2013.08.005

Date added to catalog: 2020-12-29

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	24396259	Available		24396259

Ranolazine is a novel anti-anginal agent acting through pharmacologic mechanism of inhibition of the late phase of the inward sodium current. In addition, it is a potent inhibitor of rapid delayed rectifier potassium currents, leading to prolongation of the QT interval. However, ranolazine has not yet described to be associated with Torsade de Pointes despite its QT-prolonging effect. In this case report, we describe a patient on ranolazine who developed Torsade de Pointes and discuss about the potential contribution of ranolazine to the development of Torsade de Pointes.

English